NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With RRMM Myeloma

NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

The purpose of this study is to expand upon the safety data for carfilzomib by providing expanded access to patients with relapsed and refractory multiple myeloma who are unable to enroll in any other ongoing carfilzomib trial.

Sponsor

Amgen

Collaborator

Multiple Myeloma Research Foundation

---

ClinicalTrials.gov Identifier: NCT01410500

Official Title: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

First Posted : August 5, 2011

Click here to see details on ClinicalTrials.gov

---

Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information

---

Drug: Carfilzomib

---

Location

United States